Thursday November 22, 2018 03:36

Heathcare Press Release : 14 Jun 2016

Victoza(R) significantly reduced the risk of major cardiovascular events and death in adults with Heathcare—14 Jun 16

Novo Nordisk today announced that Victoza(R) (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 Heathcare—14 Jun 16

Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes,